You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

tafasitamab

Showing 26 - 38 of 38
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Chronic Lymphocytic Leukemia, Non Hodgkin Lymphoma Trial in Worldwide (tafasitamab, parsaclisib)

Active, not recruiting
  • Chronic Lymphocytic Leukemia
  • Non Hodgkin Lymphoma
  • Birmingham, Alabama
  • +49 more
Sep 21, 2022

Leukemia, Lymphocytic, Chronic, B-Cell, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma Trial in Worldwide

Completed
Has Results
  • Leukemia, Lymphocytic, Chronic, B-Cell
  • +2 more
  • Tafasitamab
  • +2 more
  • Jacksonville, Florida
  • +16 more
Dec 10, 2021

Relapsed/Refractory Trial in Santa Fe (Tafasitamab, Lenalidomide, Tazemetostat)

Recruiting
  • Relapsed/Refractory
  • Tafasitamab
  • +8 more
  • Santa Fe, California
    California Cancer Associates For Research And Excellence, cCARE
Feb 23, 2022

Lymphoma, B-Cell Trial in Worldwide (CC-220, Polatuzumab vedotin, Rituximab)

Withdrawn
  • Lymphoma, B-Cell
  • Boston, Massachusetts
  • +26 more
Sep 28, 2021

DLBCL Trial (Tafasitamab, 12 mg/kg. 4 week cycles: weekly (Cycle 1-3) to bi-weekly (Cycle 4 onwards), loading dose Cycle 1, day

Approved for marketing
  • DLBCL
  • Tafasitamab, 12 mg/kg. 4 week cycles: weekly (Cycle 1-3) to bi-weekly (Cycle 4 onwards), loading dose Cycle 1, day 4. Cycle 4 onwards day 1, day 15 until disease progression
  • (no location specified)
Aug 26, 2020

Diffuse Large B-cell Lymphoma Trial in Worldwide (Rituximab (RTX), Tafasitamab, Bendamustine (BEN))

Active, not recruiting
  • Diffuse Large B-cell Lymphoma
  • Rituximab (RTX)
  • +2 more
  • Anaheim, California
  • +157 more
Aug 1, 2022

Relapsed or Refractory DLBCL Trial in United States (Selinexor, Rituximab, Bendamustine)

Suspended
  • Relapsed or Refractory Diffuse Large B-Cell Lymphoma
  • Tucson, Arizona
  • +17 more
Jan 24, 2023

Diffuse Large B-cell Lymphoma Trial in Worldwide (Tafasitamab, Lenalidomide, Rituximab)

Recruiting
  • Diffuse Large B-cell Lymphoma
  • Tafasitamab
  • +8 more
  • Birmingham, Alabama
  • +408 more
Aug 23, 2022

Follicular Lymphoma, Marginal Zone Lymphoma Trial in Worldwide (tafasitamab, rituximab, lenalidomide)

Recruiting
  • Follicular Lymphoma
  • Marginal Zone Lymphoma
  • tafasitamab
  • +3 more
  • Concord, California
  • +255 more
Dec 1, 2022

Lenalidomide Monotherapy in R/R DLBCL

Completed
  • Diffuse Large B Cell Lymphoma
    • Rochester, Minnesota
    • +56 more
    Aug 23, 2022

    Lymphoma, Non-Hodgkin Trial in Worldwide (CC-99282, Rituximab, Obinutuzumab)

    Recruiting
    • Lymphoma, Non-Hodgkin
    • Los Angeles, California
    • +86 more
    Jan 23, 2023

    Diffuse Large B-cell Lymphoma Trial in Worldwide (MOR00208, Lenalidomide)

    Active, not recruiting
    Has Results
    • Diffuse Large B-cell Lymphoma
    • Bakersfield, California
    • +52 more
    Sep 1, 2021

    Systemic Therapies for R/R DLBCL

    Completed
    • Diffuse Large B Cell Lymphoma
      • Scottsdale, Arizona
      • +165 more
      Oct 12, 2021